Xenon Pharmaceuticals to Showcase Innovations in Virtual Conference
VANCOUVER, British Columbia and BOSTON — Xenon Pharmaceuticals Inc. (NASDAQ: XENE), a leader in neuroscience-focused biopharmaceuticals, is excited to announce its involvement in the BofA Securities 2024 CNS Therapeutics Virtual Conference scheduled for October 7, 2024.
Details of the Presentation
Fireside Chat Presentation Schedule
The company will be participating through a live fireside chat aimed at sharing insights into their innovative approaches to tackling neurological and psychiatric disorders. Here are some important details:
- Date: Monday, October 7, 2024
- Time: 11:40 am Eastern Time
Webcast Availability
Interested individuals can access the live webcast of the presentation in the “Investors” section of Xenon’s website. The presentation will also be available for replay, ensuring that everyone has the opportunity to learn more about their remarkable advancements.
About Xenon Pharmaceuticals Inc.
Xenon Pharmaceuticals is dedicated to discovering and developing innovative therapeutics aimed at improving the lives of patients facing neurological and psychiatric challenges. Their robust pipeline includes cutting-edge treatments that address significant unmet medical needs, particularly in epilepsy and depression.
Among these is Azetukalner, which stands out as a leading Kv7 channel opener that has demonstrated clinical promise in various applications. This product is a testament to Xenon's commitment to delivering novel therapies with enduring impact.
Company Mission and Vision
'Xenon' is not just a name but a symbol of hope for many. The company’s mission centers on transforming the landscape of treatment for complex conditions that affect mental health and overall well-being. Through rigorous research and development, Xenon strives to provide new solutions that can truly change lives.
Contact Information
For further inquiries, please reach out:
For Investors
Chad Fugere
Vice President, Investor Relations
(857) 675-7275
investors@xenon-pharma.com
For Media
Colleen Alabiso
Senior Vice President, Corporate Affairs
(617) 671-9238
media@xenon-pharma.com
Frequently Asked Questions
What is the significance of this virtual conference for Xenon Pharmaceuticals?
This event allows Xenon to present its latest findings and product developments to an audience of investors and industry professionals, enhancing its visibility.
Who can access the live webcast of the fireside chat?
The webcast is open to anyone interested in learning about Xenon's initiatives and will also be available for replay after the event.
What are the main therapeutic areas Xenon focuses on?
Xenon concentrates on neurological and psychiatric disorders, particularly in under-treated conditions like epilepsy and depression.
Where can I find more information about Xenon's products?
For more details, visiting the official website of Xenon Pharmaceuticals is recommended, as it provides comprehensive information on their product pipeline and research.
How is Azetukalner positioned in Xenon's treatment arsenal?
Azetukalner is highlighted as a leading candidate in Xenon's portfolio, being developed specifically for various indications which are currently in late-stage clinical development.
